Case ReportCase Studies

Particulate Study on NeoProfen, a Neonatal Injectable Product

Aravind Krishna, Michael Rice, Tom Kester, Michael Waters and Terry Wilson
PDA Journal of Pharmaceutical Science and Technology January 2016, 70 (1) 76-92; DOI: https://doi.org/10.5731/pdajpst.2015.005587

References

  1. 1.↵
    1. Wagner C.
    Influence of Aggressive Screening Conditions and Glass Composition on the Extractables and Leachables from Glass Containers. Extractables and Leachables Europe Conference, Barcelona, Spain, 2014.
  2. 2.↵
    1. Grilli A.
    Leachable and Extractable Testing, a Primer on Regulations and Methods. 5th Annual Long Island ASQ FD&C and FDA Conference, 2007.
  3. 3.↵
    1. Iacocca R.,
    2. Toltl N.,
    3. Allgeier M.,
    4. Bustard B.,
    5. Dong X.,
    6. Foubert M.,
    7. Hofer J.,
    8. Peoples S.,
    9. Shelbourn T.
    Factors affecting the chemical durability of glass used in the pharmaceutical industry. AAPS PharmSciTech 2010, 11 (3), 1340–1349.
    OpenUrlPubMed
  4. 4.↵
    1. Popinska K.,
    2. Kierkus J.,
    3. Lyszkowska M.,
    4. Socha J.,
    5. Pietraszek E.,
    6. Kmiotek W.,
    7. Ksiazyk J.
    Aluminum contamination of parenteral nutrition additives, amino acid solutions, and lipid emulsions. Nutrition 1999, 15 (9), 683–686.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Bohrer D.,
    2. do Nascimento P. C.,
    3. Martins P.,
    4. Binotto R.
    Availability of aluminum from glass and an Al form ion exchanger in the presence of complexing agents and amino acids. Anal. Chim. Acta 2002, 495 (2), 267–276.
    OpenUrl
  6. 6.↵
    1. Bohrer D.,
    2. do Nascimento P. C.,
    3. Binotto R.,
    4. Carlesso R.
    Influence of the glass packing on the contamination of pharmaceutical products by aluminum. Part II: Amino acids for parenteral nutrition. J. Trace Elem. Med. Biol. 2001, 15 (2), 103–108.
    OpenUrlPubMed
  7. 7.↵
    1. Bohrer D.,
    2. do Nascimento P. C.,
    3. Binotto R.,
    4. Becker E.
    Influence of the glass packing on the contamination of pharmaceutical products by aluminum. Part III: Interaction container-chemicals during the heating for sterilisation. J. Trace Elem. Med. Biol. 2003, 17 (2), 107–115.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Bohrer D.,
    2. do Nascimento P. C.,
    3. Becker E.,
    4. Bortoluzzi R.,
    5. Depoi F.,
    6. de Carvalho L.
    Critical evaluation of the standard hydrolytic resistance test for glasses. PDA J. Pharm. Sci. Technol. 2004, 58 (2), 96–105.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. de Oliveira S.,
    2. Bohrer D.,
    3. Garcia S.,
    4. do Nascimento P. C.,
    5. Noremberg S.
    Aluminum content in intravenous solutions for administratin to neonates: role of product preparation and administration methods. J. Parenter. Enteral Nutr. 2010, 34 (3), 322–328.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    ECA Academy. News from the US on particles in injectables. GMP News Nov. 6, 2013 (www.gmpompliance.org/enews_4000_news_from_the_us_on_particluates_in_injectables.html).
  11. 11.↵
    1. Gallelli J. F.,
    2. Groves M. J.
    USP perspectives on particle contamination of injectable products. PDA J. Pharm. Sci. Technol. 1993, 47 (6), 289–292.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Eakins M. N.
    USP Approach to Control of Glass Containers. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  13. 13.↵
    1. Eakins M. N.
    Parenteral Glass Containers—Properties and Pharmaceopeial Control. PDA/FDA Glass Quality Conference, Arlington, VA, 2011.
  14. 14.↵
    1. Paskiet D.
    Glass Extractables: Impact to Drug Product Quality USP Methodology and Initiatives. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  15. 15.↵
    1. Eakins M. N.
    Parenteral products: pharmacopeial control of containers, storage and distribution. Am. Pharm. Rev. 2011, 14 (2), 1–3.
    OpenUrl
  16. 16.↵
    1. Tran T.,
    2. Kupiec T.,
    3. Trissel L.
    Quality-control analytical methods: particulate matter in injections. Int. J. Pharm. Compd. 2006, 10 (3), 202–204.
    OpenUrlPubMed
  17. 17.↵
    1. Schaefers M.
    Improving the quality of injectables. European Industrial Pharmacy 2013, 16, 9–12.
    OpenUrl
  18. 18.↵
    1. Langille S.
    Particulate matter in injectable drug products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Wang J.,
    2. Chien Y.
    PDA Technical Report No. 5. Sterile Pharmaceutical Packaging: Compatibility and Stability, 1984.
  20. 20.↵
    1. Shearer G.
    Identification of Particulate in Parenteral Packaging. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  21. 21.↵
    1. Shearer G.
    Using microscopical analysis methods to confirm the presence of glass delamination in parenteral vials. Contract Pharma 2014, October, 96–99.
  22. 22.↵
    1. Zuccarello D.,
    2. Murphy M.,
    3. Meyer R.,
    4. Winslow P.
    A comprehensive approach for the determination of extractable and leachable metals in pharmaceutical products by inductively-coupled plasma. PDA J. Pharm. Sci. Technol. 2009, 63 (4), 339–352.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Fitch K.,
    2. Rowe E.
    Liquid Suspension of an Aluiminum Salt of Ibuprofen. U.S. Patent 4,145,440, 1979.
  24. 24.↵
    1. Peck S.,
    2. Larion L.,
    3. Rowe E.
    Aluminum Ibuprofen Pharmaceutical Suspensions. U.S. Patent 4,361,580, 1982.
  25. 25.↵
    1. Iacocca R.,
    2. Allgeir M.
    Corrosive attack of glass by a pharmaceutical compound. J. Mater. Sci. 2007, 42 (3), 801–811.
    OpenUrl
  26. 26.↵
    1. Wagner C.
    An Alternative Glass Packaging Solution to Reduce Delamination Risks. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  27. 27.↵
    1. Guadagnino E.
    Product contact and glass interactions. PDA J. Pharm. Sci. Technol. 2012, 66 (2), 116–125.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Zuccato D.
    Glass Delamination: Risks, Reality and Regulatories. PDA Chapter Presentation, North America—Metro, December 6, 2012.
  29. 29.↵
    1. Cerdan-Diaz J.,
    2. Fitzgerald M.,
    3. Wada M.
    Utilization of a Two Prong Approach to Enhance Glass Properties and to Maximize Glass Performance. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  30. 30.↵
    1. Haines D.,
    2. Klause M.
    Approaches to Identify the Chemical Attack of Glass Vials. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  31. 31.↵
    1. Flynn C.,
    2. Hall M.,
    3. McNerney D.,
    4. Shah P.
    Glass Delamination: Risk Factors and Root Causes. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  32. 32.↵
    1. Pantano C.
    Glass Corrosion. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  33. 33.↵
    1. Varshneya A.
    Microphase Separation and Delamination in Glass. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  34. 34.↵
    1. Iacocca R.
    Glass Delamination: A Pharmaceutical Perspective. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  35. 35.↵
    1. Markovic I.
    Regulatory Perspective on Safety Qualification of Extractables and Leachables. PQRI Workshop on Parenteral and Ophthalmic Drug Products, Bethesda, MD, 2011.
  36. 36.↵
    1. Rupertus V.,
    2. Hladik B.,
    3. Rothhaar U.,
    4. Scheumann V.
    A quick test to monitor the delamination propensity of glass containers. PDA J. Pharm. Sci. Technol. 2014, 68 (4), 373–380.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Guadagnino E.,
    2. Zuccato D.
    Delamination propensity of pharmaceutical glass containers by accelerated testing with different extraction media. PDA J. Pharm. Sci. Technol. 2012, 66 (2), 116–125.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Guadagnino E.,
    2. Zuccato D.,
    3. Gloder C.,
    4. Mason D.
    An improved method to evaluate the quality of glass tubing as a raw material for pharmaceutical articles. Eur. J. Glass Sci. Technol., A 2011, 52 (6), 203–209.
    OpenUrl
  39. 39.↵
    1. Butschli J.
    Pre-testing for Delamination in Pharmaceutical Vials. Healthcare Packaging 2009, Sept. 16, 1–4. (www.healthcare-packaging.com/archives/2009/09/pre-testing_for_delamination_i.php).
  40. 40.↵
    1. Schmid B.,
    2. Zuccato D.
    Recommendations on delamination risk mitigation and prediction for Type I pharmaceutical containers made of tubing glass. On Drug Delivery 2012, January 30, 40–42 (www.ondrugdelivery.com/publications/Prefilled%20Syringes%20Jan%202012/Prefilled_Syringes_Jan_2012.htm).
  41. 41.↵
    1. Haines D.,
    2. Rothhaar U.,
    3. Klause M.,
    4. Scheumann V.
    Glass Delamination Mechanisms: An Update. PDA/FDA Glass Quality Conference, Washington, DC, 2012.
  42. 42.↵
    1. Cerdan-Diaz J.,
    2. Fitzgerald M.
    Improving Chemical Durability and Resistance to Corrosion/Delamination through Chemistry Enhancement in Glass Manufacturing. PDA/FDA Glass Quality Conference, Arlington, VA, 2011.
  43. 43.↵
    1. Haines D.,
    2. Klause M.
    Analytical Techniques to Predict Glass Delamination. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  44. 44.↵
    1. Haines D.,
    2. Scheumann V,
    3. Rothhaar U.
    Glass flakes. Contract Pharma 2013, June, 92–98.
  45. 45.↵
    1. Haines D.
    Evaluating parenteral packaging for glass delamination. Pharm. Technol. 2013, 37, 46–48.
    OpenUrl
  46. 46.↵
    1. Borchert S.,
    2. Ryan M.,
    3. Davison R.,
    4. Speed W.
    Accelerated extractable studies of borosilicate glass containers. J. Parenter. Sci. Technol. 1989, 43 (2) 67–79.
    OpenUrlPubMed
  47. 47.↵
    1. Sloey C.,
    2. Gleason C.,
    3. Phillips J.
    Determining the delamination propensity of pharmaceutical glass vials using a direct stress method. PDA J. Pharm. Sci. Technol. 2014, 67 (1), 35–42.
    OpenUrl
  48. 48.↵
    1. Phillips J.
    Vial Delamination Screening Methods. Rx-360 Symposium on Glass Delamination, Arlington, VA, 2011.
  49. 49.↵
    U.S. FDA Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs. FDA: Rockville, MD, March 2011 (www.fda.gov/drugs/drugsafety/ucm248490.htm).
  50. 50.↵
    1. Bacon F.,
    2. Raggon F.
    Promotion of attack on glass and silica by citrate and other anions in neutral solution. J. Am. Ceramic Soc. 1959, 42 (4), 195–205.
    OpenUrl
  51. 51.↵
    1. Siddiqui A.,
    2. Rahman Z.,
    3. Khan S.,
    4. Awotwe-otoo D.,
    5. Khan M.
    Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. Int. J. Pharmaceutics 2014, 473 (1), 545–551.
    OpenUrl
  52. 52.↵
    1. Nakamura K.,
    2. Yokohama S.,
    3. Sonobe T.
    Failure of stability prediciton for minodronic acid injectable by accelerated stability testing. Int. J. Pharmaceutics 2002, 241 (1), 65–71.
    OpenUrl
  53. 53.↵
    1. Trier F.
    The Glass Surface and Ways of Its Modification. Glassman Europe 2007 Conference, Prague, Czech Republic, May 9, 2007.
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Particulate Study on NeoProfen, a Neonatal Injectable Product
Aravind Krishna, Michael Rice, Tom Kester, Michael Waters, Terry Wilson
PDA Journal of Pharmaceutical Science and Technology Jan 2016, 70 (1) 76-92; DOI: 10.5731/pdajpst.2015.005587
Twitter logo Facebook logo Mendeley logo

Jump to section